Literature DB >> 12603425

Loss of CD38 correlates with simultaneous up-regulation of human leukocyte antigen-DR in benign prostatic glands, but not in fetal or androgen-ablated glands, and is strongly related to gland atrophy.

G Kramer1, G E Steiner, P Sokol, R Mallone, G Amann, M Marberger.   

Abstract

OBJECTIVE: To determine whether CD38 loss in benign and malignant prostatic disease is related to human leukocyte antigen (HLA)-DR up-regulation, by assessing the histopathology of the prostate and the effect of androgen deprivation.
MATERIALS AND METHODS: Serial sections of frozen fetal (eight), infant (six), normal adult (10), benign hyperplastic (BPH, 24), and primary (10) and hormone-treated (11) carcinomatous human prostatic tissues were analysed by immunohistology for anti-CD38 and HLA-DR antigens.
RESULTS: In BPH samples there was a significant correlation between CD38 loss (mean 21% of acini) and HLA-DR up-regulation (mean 20%; P < 0.001). Moreover, 76% of all CD38-negative acini in BPH had HLA-DR up-regulation in the same prostate epithelial cells, predominantly in atrophic and cystic glands, and in cells with retained secretions (74%). In contrast to the uniform expression in normal adult prostate, CD38 was negative or partly expressed in fetal acini (mean 19%) and almost completely negative in acini of the early infant period (mean 0.7%). In contrast to BPH, cancer cells did not selectively up-regulate HLA-DR when CD38 was lost. In patients with cancer treated by androgen deprivation, cancer cells were CD38-negative.
CONCLUSIONS: The absence of CD38 and presence of HLA-DR expression in prostatic epithelium is consistent in BPH and tissue surrounding tumour, and strongly related to gland atrophy. This is particularly interesting as HLA-DR triggering can induce apoptosis of cells, whereas CD38 prevents it. A permissive role for androgens to maintain full CD38 expression in epithelial cells is suggested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12603425     DOI: 10.1046/j.1464-410x.2003.04091.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

Authors:  G Kramer; D Mitteregger; A Maj-Hes; S Sevchenco; W Brozek
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 2.  Inflammatory mediators in the development and progression of benign prostatic hyperplasia.

Authors:  Cosimo De Nunzio; Fabrizio Presicce; Andrea Tubaro
Journal:  Nat Rev Urol       Date:  2016-09-30       Impact factor: 14.432

Review 3.  Therapeutic Applications of Functional Nanomaterials for Prostatitis.

Authors:  Chun-Ping Liu; Zi-De Chen; Zi-Yan Ye; Dong-Yue He; Yue Dang; Zhe-Wei Li; Lei Wang; Miao Ren; Zhi-Jin Fan; Hong-Xing Liu
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

4.  Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion.

Authors:  Yu Fan; Shuai Hu; Jie Liu; Fei Xiao; Xin Li; Wei Yu; Yun Cui; Mengkui Sun; Tianjing Lv; Qun He; Jie Jin
Journal:  Mediators Inflamm       Date:  2014-04-06       Impact factor: 4.711

5.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01

6.  CD38 is methylated in prostate cancer and regulates extracellular NAD.

Authors:  Jack Mottahedeh; Michael C Haffner; Tristan R Grogan; Takao Hashimoto; Preston D Crowell; Himisha Beltran; Andrea Sboner; Rohan Bareja; David Esopi; William B Isaacs; Srinivasan Yegnasubramanian; Matthew B Rettig; David A Elashoff; Elizabeth A Platz; Angelo M De Marzo; Michael A Teitell; Andrew S Goldstein
Journal:  Cancer Metab       Date:  2018-09-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.